Oral contraceptive continuation along the US-Mexico Border: Does a prescription matter?

Joseph E. Potter, Sarah McKinnon, Daniel Grossman, Kristine Hopkins, Jon Amastae, Michele Shedlin, Daniel A. Powers

Since their introduction nearly 50 years ago, oral contraceptive pills (OCPs) have become one of the most effective and widely used family planning methods worldwide. New, lower-dose formulations also make OCPs one of the safest options (Grimes 1992). The circumstances under which OCPs are sold to women, however, vary considerably across countries. One of the main differences is whether a doctor's prescription is required before a woman can purchase OCPs. In the United States (US), hormonal contraceptives require at least a health care provider's prescription if not a physical examination, which some public health experts consider unjustified (Stewart et al 2001). In neighboring Mexico, while OCPs are prescription-only in theory, in practice they are readily available from pharmacies without a prescription. Policy debate about relaxing the US prescription requirement for OCPs has focused on whether over-the-counter access (OTC) is safe and how it might influence use (Trussell et al. 1993; Grossman 2008; Jarvis 2008).

A specific question, still unresolved empirically, is what effect making the pill available over-the-counter in the United States might have on contraceptive continuation rates. Those who are against OTC access for OCPs have argued that medical supervision facilitates better use of the pill, and proper management of potential side effects. In this view, women accessing the pill at a pharmacy without a prescription would be likely to have lower continuation rates than women who were receiving the medical supervision that the prescription requirement ensures (Jarvis 2008). On the other hand, those in favor of OTC access have argued that the prescription requirement impedes access to this method of contraception, and that if the pill were available without a prescription at pharmacies continuation rates would actually increase on this account (Grossman 2008).

To assess the influence that OTC access might have on OCP continuation rates, we carried out a prospective survey of oral contraceptive users in El Paso, Texas--a unique setting along the US-Mexico border where US residents have the option of obtaining OCPs at pharmacies without a prescription at a cost of about US$5.00 per cycle. The border separating El Paso from Ciudad Juarez, Mexico is quite porous; four bridges link the two cities, and thousands cross frequently in both directions for commerce, family, recreation, education and services, such as health. Previous studies have established that health services in Mexico are an important resource for many residents in El Paso and other Texas border cities due to reasons such as lower cost, convenience, family networks, cultural comfort, perceived quality of care, and a different regulatory system (Amastae and Fernández 2006; Bastida et al. 2008; Fernández et al. 2007).

In El Paso, many US resident pill users obtain their OCPs from pharmacies in Ciudad Juarez without a prescription. In a postpartum survey carried out in the late 1990s, Potter and colleagues (2003) found that, in a sample of 1,312 multiparous lower-income mothers in

El Paso, 42% of pill users and 54% of injectable users procured their contraceptives in Mexico. In a more recent study of women's ability to self-screen for oral contraceptives using a convenience sample recruited at two shopping malls and a flea market in El Paso, 29 percent of 253 hormonal users, most of whom were on the pill, reported purchasing their method at a Mexican pharmacy (Grossman et al. 2008).

In addition to comparing OTC pharmacy users with clinic users, the information collected in our detailed baseline and follow-up questionnaires also allowed us to investigate an additional issue regarding the provision of OCPs that bears on the relationship between access and continuation. Foster et al. (2006) showed that, in California, women who were provided with 13 packs had higher continuation, and lower use of pregnancy tests compared to women who were given 1 or 3 cycles of pills. Chinn-Quee et al. (2009) compared provision of a single versus multiple packs of pills to new users in Jamaica, and also found that women provided with more pills had higher rates of continuation. If the number of pill packs a woman was given when she obtained pills effectively increases access and increases continuation, then it is important to control for this variable when comparing the continuation rates of clinic users with OTC (Mexican) pharmacy users.

In this paper, we present life table results that compare continuation rates over a nine month period for a sample of pill users who had obtained their pills at baseline at a family planning clinic in El Paso, Texas, USA with a sample of El Paso resident users who had obtained their pills over-the-counter at a pharmacy across the border in Ciudad Juarez, ~~Juárez~~, Mexico. We then carry out a hazards analysis of method related discontinuation adjusting for duration of use at baseline, marital status and parity, as well as source at baseline and the number of pill packs at last supply as/time-varying covariate.[a]

Methods

Our goal was to recruit current pill users aged 18 to 44 stratified in two groups: 1) El Paso residents who use OCPs obtained at family planning clinics in El Paso (target n=500); and 2) El Paso residents who use OCPs obtained at pharmacies in Ciudad Juárez (target n=500). Most clinic users were recruited from the major family planning providers in El Paso such as the Women's Health Center at Thomason Hospital and four Planned Parenthood clinics in El Paso. However, recruiting pharmacy users at pharmacies in Ciudad Juárez proved to be impractical. In the end, virtually the entire pharmacy user sample and a considerable proportion of the clinic sample, were recruited using announcements, flyers, presentations at local community centers, as well as through referrals from current participants. The participants resided in over 30 different zip codes in the El Paso metropolitan area. The sample was not stratified by level of education or SES, but since it was limited to users of family planning clinics and users who obtained their pills from pharmacies in Ciudad Juárez, it did not typically include women who used their health insurance or personal funds to obtain prescriptions from private sector doctors and then bought their OCs at pharmacies in the US. In fact, the majority of study participants lived in sectors of the city where the average household income fell below the 2004 median income for the city.

After obtaining signed informed consent from participants who agreed to take part in the study, we administered an hour long face-to-face baseline interview. Bilingual project staff conducted interviews in either Spanish or English in the respondent's home or a place

of her choosing. Participants were offered a small compensation in the form of gift cards to a national chain store for completing the interview. This study was approved by the Institutional Review Boards at the University of Texas at Austin and University of Texas at El Paso.

The baseline questionnaire contained a wide range of items related to the participant's background: marital status, parity, health status, medical history, use of health services, knowledge of how to use the pill, contraceptive history, and reproductive intentions. Special emphasis was given to a series of items intended to gauge the participant's ability to take advantage of Mexican pharmacies as a contraceptive source such as her contacts and relationships in Mexico, her ability to speak Spanish, and the frequency with which she crossed the border. We also asked about the participant's country of birth, level of education and the country in which she completed her last year of schooling. The baseline questionnaire also collected detailed information on women's pill use history, focusing on their recent use. We asked for the month and year a participant obtained her last pack(s), the number of packs acquired at that time, where she got her pill packs, and whether she had ever asked someone else to buy pill packs for her in Ciudad Juárez.

The second and third interviews took place approximately three and six months after the initial interview. These interviews were administered via telephone and lasted 15-20 minutes. In the telephone interviews, women were asked about changes in their health and their pill use practice during the prior three months, as well as follow-up questions on contraceptive knowledge. The final (time 4) interviews are scheduled approximately nine months after the baseline interview. They were conducted in person, either in the participant's home or other location of her choosing and took about one hour to complete.

Recruiting for the study began in December 2006 and ended in February 2008, at which point we had successfully recruited over 1000 participants. In total, we collected 1046 baseline interviews (514 women who obtained OCs from Mexican pharmacies and 532 women who obtained OCs from El Paso family planning clinics), 965 time 2 follow-up interviews, 936 time 3 follow-up interviews, and 941 time 4 final interviews. Retention was a high priority, and we implemented a variety of strategies to attain this goal such as hiring interviewers with strong ties to the El Paso community, using an interview tracking system to identify when participants needed follow-up interviews, gathering extensive contact information, and providing modest incentives to women at the end of each interview. Overall retention for all rounds was 90%, with only 105 women lost to follow-up.

For this study, following Westhoff et al. (2007), we defined OCP discontinuation as having not taken any active oral contraceptive pill for more than seven days, and probed in each interview for any lapse of this or greater length. If the woman reported stopping, we asked for the date of discontinuation (day, month, year) as well as the reason for stopping. In addition to 13 precoded reasons, we probed with an open-ended question about why the respondent stopped. On the basis of both the precoded and textual responses, we recoded the reason for stopping into four categories: 1) got pregnant while using the pill, 2) stopped in order to become pregnant or because of no longer having a need for contraception, 3) to switch to another method, and 4) because of side effects, problems taking the pill, and other reasons. In the analysis, we distinguished between discontinuation for any reason, and discontinuation due either to pregnancy or a problem with taking the pill (categories 1 and 4) (Vaughan et al. 2008).

We separated exposure to the risk of discontinuation into separate segments corresponding to the intervals between interviews (approximately 90 days) for a maximum of three segments. The two time-varying covariates, union status and number of pill packs received at last supply, were fixed at the beginning of the respective interval, and updated by way of the information obtained at the following interviews. While we are able to update source of contraception on the basis of information obtained during the follow-up interviews, for this analysis we hold source constant on the basis of whether the respondent was a clinic or pharmacy user at the baseline interview.

We calculated the life tables for clinic and pharmacy users using nine 30 day periods. In these tables, duration is based on time elapsed since the baseline interview rather than the overall duration of the segment. We ran the hazard models using Cox proportional hazards in Stata 10.1 (command "stcox"), and used proportionality tests ("stphtest") and the Ephron method in the case of ties. The covariates used in the hazards models in addition to duration of the segment at the baseline interview were selected by way of rotating a large number of possible predictors through the models, and retaining those that were either associated with continuation or the number of pill packs dispensed at last supply for clinic users.

Results

Our final analytical sample includes 965 subjects who completed a second interview, and thus contributed exposure for analysis. Of them, 493 were El Paso clinic users, and 472 were El Paso resident OCP users whose source at baseline was a pharmacy in Ciudad Juarez, Mexico. The distribution of these samples according to parity, age, education, nativity and place of last year of schooling, and duration of the current segment of pill-use at baseline is shown in Table 1, along with the proportion discontinuing use during the period of observation. Note that there are surprisingly few pill users in this sample who have not had children, a characteristic of pill users in El Paso that appeared in an earlier sample of contraceptive users in El Paso and which differs considerably from the overall Hispanic or Mexican origin population of the United States (Potter et al. 2003).

These women generated a total of 2,568 segments of approximately 90 days duration, distributed between the two samples as shown in Table 2. The distribution of time-varying covariates for these segments is shown in Table 3. There are slightly more segments spent single among clinic users. On the other hand, there is a noticeable difference in the number of pill packs dispensed between the two samples. Pharmacy users are much more likely to have obtained only one or two cycles the last time they acquired contraception.

The life table results for all cause continuation are shown in Table 4 and Figure 1 separately for the two samples. The nine month continuation rates are high for both samples with 76 percent "surviving" (continuing to use pills) among clinic users, and 79 percent among pharmacy users. This difference is not statistically significant. The difference between the two samples increases somewhat for discontinuation due to pregnancy, side effects, or other reasons, as shown in Table 5 and Figure 2. There the nine month continuation rates in the associated single decrement life tables are 81 and 85 percent respectively, and the log-rank test for equality of survivorship tests can be rejected at $p = 0.057$ level.

Before turning to the multivariate analysis of the risk of discontinuation due to an unplanned pregnancy, side-effects, or other method related reasons, we turn to the association we found in this study between the number of pill packs dispensed at last supply for clinic users with a composite variable based on parity and union status. Table 6 shows that mothers were much more likely to have been given six or more pill packs than were women who had not yet had a child, and that among mothers, those who were married or in union received more pills than did single or divorced or separated mothers.

Table 7 shows the estimated hazards ratios and p-values for clinic users relative to Mexican pharmacy users according to the number of pill packs received at last supply. Also shown are the estimated hazards ratios for the respective categories of the three covariates that were included in the final model: Duration of the segment at baseline, years of education completed, and our composite parity and marital status variable. Relative to pharmacy users, the hazards of discontinuation for contraceptive failure or side-effects were more than fifty percent higher for clinic users who received less than six cycles than they were for Mexican pharmacy users ($p < 0.05$). On the other hand, clinic users who received six or more cycles had discontinuation rates that were about 25 percent lower than those of pharmacy users, but the difference was not statistically significant.

Discussion

The first and main finding of this study is that continuation rates for El Paso resident OCP users who obtained their method from a pharmacy in Mexico were at least as high as those for a comparable sample of women who received OCPs from a family planning clinic in El Paso. Thus, this study lends no support to the proposition that withdrawing the prescription requirement for birth control pills would lead to lower continuation rates. Rather the results indicate that lowering access barriers increases contraceptive continuation. Indeed, the implication of our analysis is that both making pills available OTC <u>and</u> increasing the number of pill packs dispensed by clinics could help to increase OCP continuation rates in the US.

While the purpose of this study was to monitor a "natural experiment" whereby US residents had access to oral contraception without a prescription, we should note that the access El Paso residents have to this method of birth control is not completely equivalent to that which would be the results of making pills OTC in the US. On the one hand, the price per cycle of OCPs in Ciudad Juarez pharmacies is quite low, and to make OCPs available OTC at US$5.00 per cycle might not be feasible. On the other hand, having to cross an international border in order to get to a pharmacy is, at least for some users, a considerable hurdle. Thus, a true OTC option for OCPs would likely provide considerably easier access than is currently available to El Paso residents.

Both a limitation and strength of this study is that it is restricted to a low-income, largely Hispanic population. It is clearly difficult to generalize these results to the entire population of pill users in the US. However, it is important to note that access appears to have a strong influence on continuation in such an underserved segment of the population. It is also interesting that, in these data, neither low levels of education, nor being born or educated in Mexico were predictors of decreased continuation rates. Indeed, the only significant predictors of continuation found in this study were those related to access.

One parenthetical finding of this study is the relationship between the number of pill packs provided at a clinic and motherhood/marital status. We are inclined to believe that the strong association we found is the product of provider decisions or operating procedures rather than a reflection of differences in women's requests or expectations about how long they will use the pill. When asked at baseline, over 95 percent of clinic users in each of these groups said they expected to be using the pill for four or more months, and at least 85 percent in each group said they expected to be using the pill a year or more. Thus, in this setting, changing clinic policy to provide six or more pill packs to any client who expects to use the pill for at least six months could have an immediate and significant impact on continuation.

Acknowledgement

References

Amastae J. and Fernandez L. 2006. "Transborder use of medical services among Mexican American students in a U.S. border university", *Journal of Borderland Studies* 21(2): 77-87.

Bastida E, et al. 2008. "Persistent Disparities in the Use of Health Care Along the US-Mexico Border: An Ecological Perspective", *American Journal of Public Health* 98(11): 1987-1995.

Chinn-Quee, D., C. Otterness, et al. (2009). "One versus multiple packs for women starting oral contraceptive pills: a comparison of two distribution regimens." *Contraception* 79(5): 369-374.

Fernandez L, et al. 2007. "Education, race/ethnicity and out-migration from a border city", *Population Research and Policy Review* 26(1): 103-124.

Foster, D. G., Parvataneni R, de Bocanegra HT, Lewis C, Bradsberry M, Darney P. 2006. "Number of oral contraceptive pill packages dispensed, method continuation, and costs". *Obstetrics & Gynecology* 108(5):1107-14.

Grimes, D. A. 1992. "The safety of oral contraceptives: epidemiologic insights from the first 30 years". *American Journal of Obstetrics and Gynecology* 166(6, Part 2):150-154.

Grossman, D. 2008. "Should the contraceptive pill be available without prescription? Yes." *BMJ* 337: a3044-.

Grossman, D., L. Fernandez, et al. 2008. "Accuracy of self-screening for contraindications to combined oral contraceptive use." *Obstetrics & Gynecology* 112(3): 572-8.

Jarvis, S. 2008. "Should the contraceptive pill be available without prescription? No." *BMJ* 337: a3056.

Potter, J. E., A. M. Moore, and T. L. Byrd. 2003. "Cross-Border Procurement of Contraception: Estimates from a Postpartum Survey in El Paso, Texas," *Contraception* 68(4): 281-287.

Stewart, F. H., C. C. Harper, et al. 2001. "Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence." *JAMA* 285(17): 2232-2239.

Trussell, J., F. Stewart, M. Potts, F. Guest, and C. Ellertson. 1993. "Should oral contraceptives be available without prescription?" *Am J Public Health* 83(8):1094-1099.

Vaughan, B., J. Trussell, et al. 2008. "Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth." *Contraception* 78(4): 271-283.

Westhoff, C. L., S. Heartwell, S. Edwards, M. Zieman, G. Stuart, C. Cwiak, A. Davis, T. Robilotto, L. Cushman, D. Kalmuss. 2007. "Oral contraceptive discontinuation: do side effects matter?" *American Journal of Obstetrics and Gynecology* 196(4): 412.e1-412.e7.

Table 1. Characteristics of pill users by source of pill[1]

	El Paso clinic	Mexican pharmacy
	%	%
Parity		
0 live births	18.7	11.7
1 or more live births	81.3	88.4
Education		
Less than 9th grade	15.0	23.6
9th-11th grade	28.4	27.8
12th grade	25.8	26.1
More than 12th grade	30.8	22.5
Duration of pill use at baseline		
Short duration (less than 200 days)	31.5	23.1
Medium duration (200-1500 days)	44.4	47.2
Long duration (greater than 1500 days)	24.1	29.7
Discontinued pill use	23.7	20.8
Reason for pill discontinuation		
Got pregnant	13.7	14.3
Switched methods	4.3	9.2
Wanted to get pregnant	18.0	21.4
Side effects/other reasons	64.1	55.1
	(n=493)	(n=472)

[1]Source at baseline

Table 2. Number of responses in each segment by source of pill[1]

	First Segment	Second Segment	Third Segment
El Paso clinic	493	419	382
Mexican pharmacy	472	413	389

[1]Source at baseline

Table 3. Time-varying characteristics of pill-users by source of pill[1]

	El Paso clinic	Mexican Pharm.
	%	%
Partner Status		
Married/Cohabiting	70.3	64.2
Single	29.8	35.8
Number of pill packs[2]		
1-2 pill packs	28.5	70.0
3-5 pill packs	35.5	25.7
6 or more packs	36.0	4.3
Pill Dose		
Low hormone levels (30 mcg or less)	33.09	81.24
High hormone levels (35 mcg or greater)	66.91	18.76

[1]Source at baseline
[2]Number of pill packs she last purchased

Table 4. Life table for discontinuation of the pill for any reason by source of pill[1]

|	Start of interval	End of interval	Begin. total	Deaths	Lost	Survival
El Paso clinic						
	0	30	480	14	0	0.9716
	30	60	468	19	0	0.9331
	60	90	452	18	6	0.8963
	90	120	431	12	4	0.8715
	120	150	415	17	1	0.8362
	150	180	398	11	14	0.8129
	180	210	372	8	2	0.7956
	210	240	362	10	56	0.7722
	240	270	295	3	174	0.7613
Mexican pharmacy						
	0	30	461	11	0	0.9767
	30	60	450	17	0	0.9407
	60	90	432	13	4	0.9130
	90	120	416	15	0	0.8809
	120	150	404	10	0	0.8596
	150	180	394	5	12	0.8487
	180	210	377	6	0	0.8355
	210	240	370	9	54	0.8141
	240	270	308	6	204	0.7913

[1]Source at baseline

Figure 1. Pill Use Duration by Source of Pill: All Reasons for Discontinuation

Table 5. Life table for discontinuation of the pill due to pregnancy, side effects, or other reasons by source of pill[1]

|	Start of interval	End of interval	Begin. total	Deaths	Lost	Survival
El Paso clinic						
	0	30	480	13	1	0.9736
	30	60	468	13	6	0.9470
	60	90	452	13	11	0.9199
	90	120	431	11	5	0.8966
	120	150	415	13	5	0.8687
	150	180	398	7	18	0.8532
	180	210	372	5	5	0.8418
	210	240	362	9	57	0.8194
	240	270	295	2	175	0.8117
Mexican pharmacy						
	0	30	461	7	4	0.9851
	30	60	450	11	6	0.9614
	60	90	432	10	7	0.9396
	90	120	416	10	5	0.9175
	120	150	404	8	2	0.8996
	150	180	394	5	12	0.8883
	180	210	377	2	4	0.8836
	210	240	370	5	58	0.8710
	240	270	308	5	205	0.8506

[1]Source at baseline

Figure 2. Pill Use Duration by Source of Pill: All Reasons for Discontinuation for pregnancy or side effects.

Table 6. Number of pill packs[1] by parity/marital status, El Paso clinic users

	Has children/single	Has children/married	No children
	%	%	%
Number of pill packs			
1-2 packs	24.2	23.4	51.3
3-5 packs	40.8	34.5	32.6
6 or more packs	35.0	42.1	16.1

[1]Number of pill packs she last purchased

Table 7. Cox proportional hazard model for pill discontinuation due to pregnancy, side effects, or other reasons

	Hazard Ratio	P-Value
Source of Pill/Number of Pill Packs[1,2]		
Mexican pharmacy	1.00	
El Paso clinic/1-2 packs	1.59	0.04
El Paso clinic/3-5 packs	1.54	0.04
El Paso clinic/6 or more packs	0.74	0.26
Duration of pill use at baseline		
1 to 200 days	1.000	
201 to 1500 days	1.14	0.51
Greater than 1500 days	0.79	0.31
Education		
0-8 years	1.00	
9-11 years	1.18	0.56
12 years	1.51	0.12
$\geq$ 12 years	1.71	0.05
Parity/Marital Status		
Has children/single	1.00	
Has children/married	0.75	0.13
No children	0.96	0.89

[1]Source at baseline

[2]Number of pill packs she last purchased